secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptorum Group Ltd (APM)
CIK:        0001734005
Form:       8-K
Filed at:   2026-10-09T21:12:08+00:00
Accession:  0001213900-26-108572
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Niki BioSolutions signs ATM sales agreement with H.C. Wainwright for up to $1,396,000 of common stock
--------------------------------------------------------------------------------

- Sales Agreement dated October 9, 2026 lets Niki BioSolutions (NIKI) sell up to $1,396,000 of common stock through H.C. Wainwright as sales agent or principal.
- Wainwright earns a 3.0% placement fee on gross sales as agent; Brookline Capital Markets acts as qualified independent underwriter for no additional compensation.
- Director and largest shareholder Dr. Kira Sheinerman is a Wainwright managing director, creating a FINRA Rule 5121 conflict; Wainwright cannot sell to discretionary accounts without written approval.
- Offering falls under a Form S-3 shelf (File No. 333-298608) declared effective October 9, 2026; exhibits include the Sales Agreement (1.1) and Hunter Taubman Fischer & Li opinion (5.1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1734005/000121390026108572/0001213900-26-108572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1734005/000121390026108572/ea0308263-8k_nikibio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-108572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer